NGeneBio Co

NGeneBio Co Accounts Payable

The Accounts Payable of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is 5.14 B KRW. In the previous year, Accounts Payable was 376.67 M KRW — a change of 1,264.60% (higher).

Accounts Payable

5.14 BKRW

YoY

1,264.60%

Last updated:

Accounts Payable of NGeneBio Co is 2025 5.14 B KRW. Accounts Payable of NGeneBio Co was 2024 376.67 M KRW. It decreases by 1,264.60% higher compared to the previous year.

The NGeneBio Co Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2020
389.21 M KRW
Jan 1, 2021
172.85 M KRW
Jan 1, 2022
69.18 M KRW
Jan 1, 2023
162.75 M KRW
Jan 1, 2024
376.67 M KRW
Jan 1, 2025
5.14 B KRW
The NGeneBio Co Accounts Payable history
YEARAccounts PayableYoY
5.14 BKRW+1,264.60%
376.67 MKRW+131.45%
162.75 MKRW+135.27%
69.18 MKRW-59.98%
172.85 MKRW-55.59%
389.21 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

Accounts Payable of NGeneBio Co is 5.14 B KRW in 2025.

Accounts Payable of NGeneBio Co changed from 376.67 M KRW to 5.14 B KRW, representing a 1,264.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's NGeneBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — NGeneBio Co

All Key Metrics — NGeneBio Co